

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ying-Fei Wei

Docket No.: PF220C1

Application No.: 10/717,473

Confirmation No.: 7061

Filed: November 21, 2003

Art Unit: 1647

For: Transforming Growth Factor Alpha HIII

Examiner: L. Spector

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney/Agent for Applicants hereby directs the Examiner's attention to references A-AF listed on the attached Form SB/08.

Copies of references A-AF were submitted by Applicants or cited by the Examiner in connection with U.S. Application Nos. 08/778,545, filed on January 3, 1997, and 09/726,348, filed on December 1, 2000, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of U.S. Application Nos. 08/778,545 and 09/726,348 for copies of references A-AF.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS:34830, 177536, and 179175 in U.S. Patent Application No. 09/912,293 (now abandoned). A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached Form PTO/SB/08 was submitted in an Information Disclosure Statement filed by Applicants on August 16, 2002 in U.S. Application No. 08/778,545 as reference AE and was again submitted in an Information Disclosure Statement filed by Applicants on March 6, 2002 in U.S. Application No. 09/726,348 as reference AL.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such

references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.

Dated: Oct. 16, 2010

Respectfully submitted,

By  
Melissa J. Pytel

  
Registration No.: 41,512  
HUMAN GENOME SCIENCES, INC.  
Intellectual Property Dept.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 610-5764

MJP/PF/ba

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
				Application Number	10/717,473-Conf. #7061
				Filing Date	November 21, 2003
				First Named Inventor	Ying-Fei Wei
				Art Unit	1647
				Examiner Name	L. Spector
Sheet	1	of	1	Attorney Docket Number	PF220C1

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	09/912,293	Not published	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 34830, 177536, and 179175.

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	B	WO-94/01548	01-20-1994	Sibson et al.	
	C	WO-95/14772	06-01-1995	Matsubara et al.	
	D	WO-96/39497	12-12-1996	Human Genome Sciences, Inc.	
	E	WO-96/36709	11-21-1996	Human Genome Sciences, Inc.	
	F	WO-00/15666	03-23-2000	Genentech, Inc.	
	G	WO-97/25349	07-17-1997	Human Genome Sciences, Inc., et al.	
	H	WO-99/18203-A2	04-15-1999	Sagami Chemical Research Center and Proteogene Inc.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	I	BARNARD et al., <i>Journal of Biological Chemistry</i> , 269(36):22817-22822 (1994).			
	J	Supplementary Partial European Search Report dated May 4, 2000, corresponding to European Application No. 96902605.3			
	K	SCHULTZ et al, "Epithelial Wound Healing Enhanced by Transforming Growth Factor-Alpha and Vaccinia Growth Factor," <i>Science</i> , 235:350-352 (Jan. 16, 1987).			
	L	SHOYAB et al, "Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family," <i>Science</i> , 243:1074-1076 (Feb. 14, 1989).			

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete If Known</i>	
				Application Number	10/717,473-Conf. #7061
				Filing Date	November 21, 2003
				First Named Inventor	Ying-Fei Wei
				Art Unit	1647
				Examiner Name	L. Spector
Sheet	2	of	1	Attorney Docket Number	PF220C1

M	COFFEY et al, "Basic Actions of Transforming Growth Factor-Alpha and Related Peptides," Eur. Journal of Gastroenterology & Hepatology, 7(10):923-927 (1995).	
N	PRIGENTI et al, "The Type I (EGFR-Related) Family of Growth Factor Receptors and Their Ligands," Progress in Growth Factor Research, 4:1-24 (1992).	
O	Copy of International Search Report from International Application No. PCT/US00/32745.	
P	Sibson et al., GenSeq Accession No. AAQ77146 (Sep-03-1994).	
Q	Matsubara, et al., GenSeq Accession No. AAT26417 (Dec-06-1995).	
R	Hillier, L. et al., GenBank Accession No. R68940 (Jun-01-1995).	
S	Hillier, L. et al., GenBank Accession No. H02975 (Jun-20-1995).	
T	Hillier, L. et al., GenBank Accession No. H71660 (Oct-26-1995).	
U	Hillier, L. et al., GenBank Accession No. T52870 (Feb-06-1995).	
V	Hillier, L. et al., GenBank Accession No. H87685 (Nov-21-1995).	
W	Hillier, L. et al., GenBank Accession No. T39215 (Jan-27-1995).	
X	Hillier, L. et al., GenBank Accession No. T64613 (Feb-20-1995).	
Y	Hillier, L. et al., GenBank Accession No. R76590 (Jun-06-1995).	
Z	S. Sen, "Aneuploidy and cancer", Curr. Opin. Oncol. 12:82-88, 2000.	
AA	Tirosvoutis, KN et al., "Characterization of a novel zinc finger gene (ZNF165) mapping to 6p21 that is expressed specifically in testis", <i>Genomics</i> , 28(3):485-490 (1995).	
AB	Farnham, PJ et al., "Characterization of the 5' end of the growth-regulated Syrian hamster CAD gene", <i>Cell Growth Differ.</i> , 1(4):179-189 (1990).	
AC	KUMAR et al., "Transforming growth factor alpha", <i>Cell Biol. Int'l.</i> , 19(5):373-387 (1995).	
AD	NORMANNO et al. "Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma", <i>Cancer Detection and Prevention</i> , 22(1):62-67 (1998).	
AE	MCINNES et al., "Growth factor receptors: structure, mechanism, and drug discovery", <i>BioPolym.</i> , 43(5):339-366 (1997).	
AF	Partial European Search Report, Application No. EP 00 98 3862, dated March 12, 2003.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered	
-----------------------	--------------------	--